Relay Therapeutics (RLAY) Change in Acquisitions & Divestments (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Change in Acquisitions & Divestments data on file, last reported at $83.8 million in Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 29.28% year-over-year to $83.8 million in Q1 2026; TTM through Mar 2026 was $335.2 million, a 29.18% decrease from a year earlier, with the FY2025 full-year figure at $316.2 million, down 48.3% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $83.8 million, up from $69.5 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for RLAY reached as high as $203.1 million in Q1 2024 and fell as low as $18.1 million in Q1 2022.
• Historically, Change in Acquisitions & Divestments has averaged $118.5 million across 5 years, with a median of $104.1 million in 2024.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 95.31% in 2022 and jumped 867.09% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $183.0 million in 2022, then climbed by 7.43% to $196.6 million in 2023, then plunged by 47.07% to $104.1 million in 2024, then tumbled by 33.26% to $69.5 million in 2025, then grew by 20.64% to $83.8 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $83.8 million in Q1 2026, $69.5 million in Q4 2025, and $97.8 million in Q3 2025.